Clinical trials: Epicardial Fat
Heart Failure, Heart Failure, Systolic
Predicting Heart Failure Outcomes With Biomarkers and Imaging
This study aims to develop a better model to predict one-year risk of death in patients with heart failure. We will test whether combining information from routine blood tests (like NT-proBNP) and heart scans (measuring features…
- Conditions
- Heart Failure, Heart Failure, Systolic, Heart Failure, Diastolic, Heart Failure With Reduced Ejection Fraction (HFrEF)
- Trial name
- BIOPHF (NCT07332520)
- Volunteers
- 4,000 people
- Sponsor
- Xinjiang Medical University
Atrial Fibrillation (AF), CT
Cardiac CT Evaluation of EAT in AF vs. Non-AF Subjects
The goal of this cross-sectional study is to explore the relationship between atrial structural characteristics (such as epicardial adipose tissue infiltration and atrial size) and atrial fibrillation (AF), as well as the…
- Trial name
- CCT-EAT-AF-NA (NCT07320261)
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- xiaoya wang
Type 2 Diabetes, Overweight
Effect of Liraglutide on Epicardial Fat in Subjects With Type 2 Diabetes
The purpose of this research study is to learn about the effect of Liraglutide, (Victoza®), on the fat surrounding the heart.Excessive amount of the fat around the heart is common in people with type 2 diabetes and can be…
- Conditions
- Type 2 Diabetes, Overweight, Obesity
- Trial name
- NCT02014740
- Testing
- Liraglutide, Metformin
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Miami
Acute Coronary Syndrome
Epicardial Adipose Tissue Thickness PredIcts Obstructive Coronary Artery Disease in Acute Coronary Syndrome Patients
Epicardial adipose tissue (EAT) is a visceral adipose tissue that surrounds the heart and the coronary arteries. It is metabolically active, secreting pro- and anti-inflammatory mediators and cytokines.
- Trial name
- EPIC-ACS (NCT03787797)
- Testing
- Echocardiography
- Where
- Germany
- Volunteers
- 657 people
- Sponsor
- University Hospital, Essen
Essential Hypertension, Diabetes Mellitus
Effects Of Losartan On Myocardial Structure In Diabetic Hypertensive Patients With Left Ventricular
The anthypertensive treatment with Losartan may have benefits beyond blood pressure reduction on myocardial structure and function in hypertensive diabetic patients.
- Trial name
- NCT00659451
- Testing
- Losartan, Amlodipine
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- University of Pavia
Atrial Fibrillation, Ischemic Heart Disease
The New Pharmaceutical Composition Containing Botulinum Toxin to Treat Atrial Fibrillation
The aim of this prospective randomized double-blind study was to compare the efficacy of new pharmaceutical composition containing botulinum toxin injection in epicardial fat pads for preventing recurrences of atrial…
- Trial name
- NCT02982434
- Testing
- Pharmaceutical composition containing botulinum toxin, 0.9% normal saline, Coronary artery bypass grafting
- Where
- 2 sites in Russia
- Volunteers
- 180 people
- Sponsor
- Meshalkin Research Institute of Pathology of Circulation
Type 2 Diabetes
Dapagliflozin Effects on Epicardial Fat
The purpose of this research study is to learn about the effect of Dapagliflozin (Farxiga) on the fat of the heart.
- Trial name
- NCT02235298
- Testing
- Dapagliflozin, Metformin
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Miami
Pulmonary Embolism, Lung Cancer
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
The occurrence and progression of lung cancer is related to visceral adipose tissue (VAT). Epicardial adipose tissue (EAT) is a kind of VAT, producing a variety of inflammatory cytokines and adipokines, participating in the…
- Trial name
- NCT06017271
- Testing
- CTPA (computed tomography pulmonary angiography)
- Where
- China
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Paroxysmal Atrial Fibrillation, Indications for CABG
Botulinum Toxin Injection in Epicardial Fat Pads To Treat Atrial Fibrillation After Cardiac Surgery
The aim of this prospective randomized double-blind study was to compare the efficacy and safety of Botulinum toxin injection in epicardial fat pads for preventing recurrences (in early postoperative period) of atrial…
- Trial name
- NCT01842529
- Testing
- botulinum toxin injection, 0.9% normal saline injection, Implantable loop recorder
- Where
- 3 sites in United States, Russia
- Volunteers
- 60 people
- Sponsor
- Meshalkin Research Institute of Pathology of Circulation
Overweight, Obesity
Exercise Program Combined or Not With Nutritional intErvention in Adults With tyPe 2 Diabetes
Inactivity and excess energy consumption are leading causes of obesity and type 2 diabetes which are associated with increased cardio-metabolic risk.
- Conditions
- Overweight, Obesity, Type 2 Diabetes
- Trial name
- PEP-2 (NCT01186952)
- Testing
- Caloric restriction, Diet intervention and structured exercise training program
- Where
- Canada
- Volunteers
- 90 people
- Sponsor
- Institut de Recherches Cliniques de Montreal
Atrial Fibrillation, Ischemic Heart Disease
Epicardial Fat Pads Ablation During Coronary Surgery
The aim of this prospective randomized study was to assess the efficacy of ablation of the ganglionated plexi localized in the epicardial fat pads for preventing recurrences of atrial tachyarrhythmia in patients with paroxysmal…
- Trial name
- NCT02984371
- Testing
- Coronary artery bypass grafting, Epicardial ganglionated plexi ablation, implantable loop recorder
- Where
- 2 sites in Russia
- Volunteers
- 264 people
- Sponsor
- Meshalkin Research Institute of Pathology of Circulation
Heart Failure Preserved Ejection Fraction, Epicardial Adipose Tissue
Epicardial Adipose Tissue Composition and Heart Failure With Preserved Ejection Fraction
This study seeks to develop improved cardiac MRI (CMR) methods to quantify epicardial adipose tissue (EAT) composition and to demonstrate the advantages of EAT composition imaging (a) in advancing the understanding of the…
- Trial name
- NCT07178145
- Testing
- GLP-1RA
- Where
- United States
- Volunteers
- 192 people
- Sponsor
- University of Virginia
Atrial Fibrillation (AF)
Epicardial Adipose Tissue-Targeted DApagliflozin for Reducing Electrical Remodeling in Atrial Fibrillation
Persistent atrial fibrillation (PeAF) is associated with a high risk of recurrence following catheter ablation despite advances in ablation technology and strategies.
- Trial name
- EAT-DARE-AF (NCT07331727)
- Testing
- Dapagliflozin (10Mg Tab) along with standard medical therapy
- Where
- China
- Volunteers
- 280 people
- Sponsor
- Shanghai Chest Hospital
Heart Failure With Reduced Ejection Fraction
First in Humans to Evaluate Collagen Patches With Stem Cells in Patients With Ischemic Left Ventricular Dysfunction
It´s a first open-label trial in humans to evaluate the safety and efficacy of epicardial delivery of collagen patches with adipose-derived stem cells in patients with ischemic heart disease and left ventricular dysfunction that…
- Trial name
- CARDIOMESH (NCT03746938)
- Testing
- VB-C01
- Where
- 2 sites in Spain
- Volunteers
- 10 people
- Sponsor
- Viscofan
Obesity and Type 2 Diabetes
Effects of Enavogliflozin on Coronary Microvascular and Cardiac Function in Obesity
The goal of this study is to analyze the effects of enavogliflozin on heart function and coronary microvascular function in obese patients compared to a placebo, and to evaluate the improvement in cardiopulmonary exercise…
- Trial name
- ENVY (NCT06782139)
- Testing
- Enavogliflozin
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Korea University Anam Hospital
Heart Failure With Preserved Ejection Fraction
The Relationship Between Pericardial Fat Thickness and Arterial Stiffness in HFpEF Patients
Heart failure with preserved ejection fraction (HFpEF) was considered as a heterogeneous disease with multi-organ and multi-system design, which is related to various complications, such as hypertension, obesity and…
- Trial name
- NCT04594499
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Chongqing Medical University
Chronic Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF)
Precision Subtyping and Prognostic Study of Heart Failure Based on Multi-Omics Integration and Clinical Indicators: A Prospective Single-Center Cohort Study
This is a prospective single-center cohort study conducted at The First Affiliated Hospital of Xinjiang Medical University, aiming to enroll 400 patients with chronic heart failure (including HFrEF, HFmrEF, HFpEF) and 200 healthy…
- Conditions
- Chronic Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF), Heart Failure With Preserved Ejection Fraction (HFPEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
- Trial name
- HF-MultiOmics (NCT07355088)
- Where
- China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Xinjiang Medical University
STEMI - ST Elevation Myocardial Infarction, Epicardial Fat
Epicardial Cardiac Fat-CT (EPIC-CT)
Both globally and nationally, heart disease remains the leading cause of death overall and across genders, with ischemic heart disease being the primary cause.
- Trial name
- EPIC-CT (NCT07297589)
- Testing
- Dapagliflozin 10 MG Oral Tablet, Semaglutide (Rybelsus®)
- Where
- Mexico
- Volunteers
- 136 people
- Sponsor
- Instituto Mexicano del Seguro Social
Coronary Artery Disease
Epicardial Fat in Coronary Artery Disease
We hypothesize that human epicardial fat plays a thermogenic role to the myocardium. We hypothesize that epicardial fat may express genes of brown fat and thyroid function that are down-regulated by the presence of coronary…
- Trial name
- NCT03693261
- Testing
- Coronary artery bypass grafting (CABG), Valve replacement
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- University of Miami
Obesity, Diabetes
Effect of GLP-1 Receptor (GLP-1R) Agonists on Cardiac Function and on Epicardial Adipose Tissue (EAT) Volume and on Myocardial TG Content in Obese Diabetics
Glucagon-like peptide-1 (GLP-1) receptor agonist are new treatment of type 2 diabetes, they lower blood glucose level (by enhancement of glucose-dependent insulin secretion and suppression of excess glucagon secretion) and reduce…
- Trial name
- NCT02042664
- Testing
- BYETTA treatment, Metformine
- Where
- France
- Volunteers
- 44 people
- Sponsor
- Assistance Publique Hopitaux De Marseille